Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The O:2 O-antigen is the O-specific polysaccharide (OSP) component of the lipopolysaccharide (LPS) located on the outer membrane of Salmonella enterica serovar Paratyphi A [1]. It serves as a critical virulence factor and is the primary target for the development of vaccines against paratyphoid fever, a systemic infection that remains a significant public health burden in South and Southeast Asia [2, 4]. The O:2 antigen structure consists of a trisaccharide backbone of rhamnose, mannose, and galactose, with a terminal paratose residue that confers its serogroup A specificity [1, 3]. In vaccine development, this polysaccharide is often conjugated to carrier proteins such as CRM197 or tetanus toxoid to enhance its immunogenicity and induce a T-cell dependent immune response [3, 5]. These conjugate vaccines aim to elicit high levels of bactericidal antibodies that promote the clearance of the bacteria via the complement system and opsonophagocytosis [2, 3]. Clinical trials are currently evaluating bivalent formulations that combine the O:2 antigen with the Vi polysaccharide of S. Typhi to provide broad protection against enteric fever [5]. (Sources: [1] NIH/PubMed 24631090; [2] MDPI Vaccines 13(2):122; [3] MDPI Vaccines 12(11):1264; [4] WHO Paratyphoid Pipeline; [5] University of Oxford/NEJM 2025).
Induction of protective bactericidal antibodies (IgG and IgA) that target the O-antigen on the bacterial surface, facilitating complement-mediated lysis and opsonophagocytosis of Salmonella Paratyphi A.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Salmonella enterica serovar Paratyphi A O:2 O-antigen (O:2 OAg) (O:2 OAg).